From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|August 9, 2021
Pharmacy Clinical Pearl of the Day: PrEP for HIV
Author(s)Saro Arakelians, PharmD
Truvada is a medicine people at risk for HIV should take to prevent infection with the virus from various ways, such as sex or injection drug use.
Advertisement
Clinical Pearl of the Day: PrEP for HIV
- Emtricitabine and tenofovir disoproxil fumarate (Truvada) for pre-exposure prophylaxis (PrEP) is a once-daily prescription medicine for adults and adolescents at risk of HIV who weigh at least 77 pounds.
Explanation
- Truvada is a medicine people at risk for HIV should take to prevent infection with the virus from various ways, such as sex or injection drug use.
- PrEP consists of a combination of 2 antiretroviral drugs (tenofovir and emtricitabine), usually taken daily and often in combination with other HIV medicines.
- When taken consistently, the Centers for Disease Control and Prevention estimates that PrEP reduces the risk of HIV infection by up to 92%.
Reference
Advertisement
Related to this article
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Structured Blood Glucose Testing: Why Timing Matters
2
Glucose Monitoring: Timing Makes Every Reading Count
3
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
4
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
5